Portfolio manager Cathie Wood is known for having an aggressive appetite for risk when it comes to the investments she makes in her exchange-traded fund, the ARK Innovation ETF (ARKK -2.02%). Between its stakes in biotech companies with no products on the market and in rising stars like Tesla, its holdings are often in long shots that have the potential to be transformative for their industries or for the world.
On that note, there are two promising -- but speculative -- biotechnology businesses in the ARK portfolio that investors might be interested in if they're patient enough to hold onto their shares for a few years before seeing major returns. Over the next five years, Wood's thesis for both will be tested, so people who buy shares now could join in her eventual profits -- or her losses, which have been substantial for both stocks over the last 12 months.
CRISPR Therapeutics (CRSP -2.68%) is a gene-editing biotech that is working to develop cures for hereditary conditions including sickle cell disease and beta-thalassemia. Before the end of 2022, it expects to ask regulators at the Food and Drug Administration to approve the gene therapy exa-cel, which it claims can functionally cure both diseases. That means sometime in 2023, it could be realizing revenue from sales of its treatments for the first time ever, which will be a major catalyst for the stock.
But CRISPR's true potential actually lies beyond exa-cel. It's also investigating a handful of candidates as off-the-shelf immunotherapies that could treat different cancers, among them lymphoma. The off-the-shelf aspect is what differentiates these programs from the immunotherapies in development by most other companies, and it's also the most exciting thing about CRISPR.
A common problem with sophisticated cell therapies made using genetic engineering is that the patient's body may reject the cell therapy upon infusion. To get around that issue, biopharmas use each patient's own cells as the starting material to manufacture their specific therapy. That's effective, but it's also tremendously expensive because of the costs involved with drawing a sample, shipping it to a manufacturing site, processing it to make a single person's therapy, and then shipping it back to be infused into the patient.
What CRISPR hopes to do is produce non-personalized immunotherapies that don't trigger rejection. If it succeeds, its treatments will be far more scalable to manufacture, far more profitable to sell, and maybe even more effective than those produced by its competitors. That possibility is exactly what Wood is betting on with her investment, but it's almost certain to take a bit longer than a year or two to come to fruition because of how ambitious the goal is.
If you're willing to take a risk that CRISPR won't ever be able to figure it out for the chances of outsized rewards if it does, this is a good stock to buy.
Intellia Therapeutics (NTLA -5.54%) also plans to use advanced gene-editing techniques to treat people's genetic diseases. Like CRISPR Therapeutics, it doesn't have any revenue outside of what it makes from collaborations -- and that only totaled around $33 million in 2021. In terms of its pipeline, it has an early-stage program for sickle cell disease, and other early-stage programs aiming to address transthyretin amyloidosis, a rare hereditary liver disease.
Excitingly, its therapies for those conditions could be curative, though management is careful to remind investors that those treatments could still deliver much-needed relief to patients for long periods without being complete cures, technically speaking. But it isn't anywhere close to commercializing any of its therapies, so it's definitely a stock you'll need to hold onto for at least three or four years before it has the possibility of delivering major returns.
Furthermore, Intellia is developing capabilities similar to CRISPR's with regard to off-the-shelf immunotherapies, though CRISPR's are further advanced. It's pretty clear that Wood bought into Intellia to diversify her bet on easily scalable immunotherapies and give herself two opportunities to succeed. It might make sense for you to do the same if you're looking to hedge your other gene-editing stock plays.
Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics, Intellia Therapeutics, and Tesla. The Motley Fool has a disclosure policy.
Read more:
2 Risky Cathie Wood Growth Stocks to Buy and Hold for 5 Years - The Motley Fool
- Principles of Genetic Engineering - PMC - National Center for ... - March 28th, 2024
- Historic Overview of Genetic Engineering Technologies for Human Gene ... - March 28th, 2024
- 20.3: Genetic Engineering - Biology LibreTexts - December 10th, 2023
- Genetically modified organism - Wikipedia - November 16th, 2023
- Genetic engineering - DNA Modification, Cloning, Gene Splicing - November 16th, 2023
- 18 Human Genetic Engineering - Clemson University - April 7th, 2023
- Pros and Cons of Genetic Engineering - Benefits and Risks - April 7th, 2023
- Genetic Engineering - Meaning, Applications, Advantages and Challenges ... - March 12th, 2023
- Genetic Engineering Principles of Biology - December 27th, 2022
- Engineering the Perfect Baby | MIT Technology Review - December 27th, 2022
- What is CRISPR? | Live Science - November 24th, 2022
- To modify or not to modify? Genetic Modification and Gene Editing - A divergence by the UK - Lexology - October 13th, 2022
- DNA and the impossibility of research in isolation - Morning Star Online - October 13th, 2022
- Genome editing technologies: final conclusions of the re-examination of Article 13 of the Oviedo Convention - Council of Europe - October 13th, 2022
- Approval, Commercialization Highlighted at Cell & Gene Meeting on the Mesa - Genetic Engineering & Biotechnology News - October 13th, 2022
- Dissatisfaction and New Articulations - Discovery Institute - October 13th, 2022
- In 'The Cultivar Series,' Uli Westphal Gets to the Root of Crop Diversity and Agricultural Modification - Colossal - October 13th, 2022
- Genomic Research Aids in the Effort to Understand How Best to Treat Deadly Infections Caused by a Fungus - UMass News and Media Relations - October 13th, 2022
- Synthetic Biology Market is Expected to Report a CAGR of ~21% from 2021 to 2029: Industry Size, Growth & Forecast at Douglas Insights - Yahoo... - October 13th, 2022
- Farmers, consumers will embrace GMOs if they understand them - The Standard - October 13th, 2022
- Emily Whitten: The limits of science and human intelligence - WORLD News Group - October 13th, 2022
- Behind this Nobel prize is a very human story: theres a bit of Neanderthal in all of us - The Guardian - October 13th, 2022
- Earth materials in technology The National - The National - October 13th, 2022
- Gene therapy brings hope to people with sickle cell, HIV - Monitor - October 13th, 2022
- Eligo Bioscience Receives FDA Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) Designation for EB003 for the Prevention of Hemolytic... - October 13th, 2022
- Skin Grafting, Cryopreservation, and Diseases: A Review Article - Cureus - October 13th, 2022
- Cultured meat could help solve the climate crisis. Heres what it will take to move it from the lab to the dinner table - Fortune - October 13th, 2022
- Ignore scary messages: We've never had it so good & that's not manure - West Side Index & Gustine Press-Standard - October 13th, 2022
- Global Phosphoramidite Market Report 2022: Increasing Synthetic Nucleotide Applications in Therapeutics Drives Growth - ResearchAndMarkets.com -... - October 13th, 2022
- Enzymes Market worth $16.9 billion by 2027 - Exclusive Report by MarketsandMarkets - Yahoo Finance - October 4th, 2022
- Experts Sound Alarm Over 'Growing Threat' of Genetically Engineered Trees - Common Dreams - October 4th, 2022
- Scientists are manipulating the DNA of mosquitoes to fight the spread of malaria - Euronews - October 4th, 2022
- Smile Coffee Werks upgraded its coffee beans to Fair Trade and USDA Organic - Vending Market Watch - October 4th, 2022
- COVID mRNA Jabs and Testing Kicked Off This Industry of Drug Development: Here's What You Need to Know - The Epoch Times - October 4th, 2022
- 22nd Century Group (Nasdaq: XXII) Expands VLN Distributor Network with the Addition of Specialty Distrib - Benzinga - October 4th, 2022
- Researchers are seeking to develop spuds that resist harmful nematodes - FreshPlaza.com - October 4th, 2022
- Synthetic biology has the power to cure and kill. How will we use it? - Big Think - September 25th, 2022
- SPECIAL REPORT: Bioengineered food labeling: 'They kind of shot in the middle and missed every constituency' - FoodNavigator-USA.com - September 25th, 2022
- Yeast-Fermented Chemo: Now We Can Brew Anything - Medscape - September 25th, 2022
- September 23, 2022: The Integrity of Marius Mason WFHB - WFHB News - September 25th, 2022
- Bananas threatened by devastating fungus given temporary resistance - New Scientist - September 25th, 2022
- 'What Hath God Wrought' - Today, Luddites Are Concerned About Weedkillers Like They Once Were The Telegraph - Science 2.0 - September 25th, 2022
- Children should be educated about oral health and hygiene - Star of Mysore - September 25th, 2022
- Id rather eat an actual burger: why plant-based meats sizzle fizzled in the US - The Guardian - September 25th, 2022
- Health Tech startups are booming. These 11 VC investors are behind some of the hottest deals - Fortune - September 25th, 2022
- Last Chance This Fall to Tell the NOSB To Uphold Organic Integrity - Beyond Pesticides - September 25th, 2022
- Cambodian PM begins official visit to Cuba - Khmer Times - September 25th, 2022
- Researchers develop method to prevent spread of melanoma to brain - Xinhua - September 25th, 2022
- I'm allergic to the cat, what can I do? - Surinenglish.com - September 25th, 2022
- Researchers Propose a New Way of Regulating Engineered Crops - Modern Farmer - September 16th, 2022
- Purple Tomato is first genetically engineered plant to be deregulated through USDA's new regulatory status review process - Lexology - September 16th, 2022
- Genetically Modified Feed Market to Hit $135 billion by 2030, says Global Market Insights Inc. - Yahoo Finance - September 16th, 2022
- Africa, GMOs and Western Interests - DW (English) - September 16th, 2022
- The science behind the oil supply breakdown in 'Last Light' - Syfy - September 16th, 2022
- Inside the controversial plan to bring extinct animals back from the dead - The Independent - September 16th, 2022
- Star Trek Actor Says Their Trek Hero Is Just Like Their Marvel Character - Giant Freakin Robot - September 16th, 2022
- Scientists closer to making blood stem cells in the lab - Cosmos - September 16th, 2022
- Oncolytic Cancer Therapies Market is expected to grow at a CAGR of 33% by 2032 | DelveInsight - Digital Journal - September 16th, 2022
- Don't call it waste - it can be turned into hydrogen if you handle it right - Innovation Origins - September 16th, 2022
- Can gene editing ease the cost of living crisis? - The Grocer - September 8th, 2022
- Gene editing could revive the American chestnut tree and help fight climate change but familiar anti-biotechonology activist critics will have none... - September 8th, 2022
- Colossal to de-extinct the Tasmanian tiger. Is it a safe thing to do? - Cape Cod Times - September 8th, 2022
- The Future of Nanotech, the World's Tiniest Industry - Entrepreneur - September 8th, 2022
- Viewpoint: The 'natural food' sham 'Effective communication on the ethics of science may be hindered by appeals to naturalness' - Genetic Literacy... - September 8th, 2022
- Toray says it has developed the worlds first 100% bio-based adipic acid - Biofuels Digest - September 8th, 2022
- Chinese scientists claim to have engineered the world's first mouse with fully reprogrammed genes - Interesting Engineering - August 30th, 2022
- Century Therapeutics Receives Study May Proceed Notification from FDA for CNTY-101, the First Allogeneic Cell Therapy Product Candidate Engineered to... - August 30th, 2022
- Living Carbon: The startup setting down roots from 9 to 5 | Greenbiz - GreenBiz - August 30th, 2022
- Novavax Nuvaxovid COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization in the United Kingdom for Use in Adolescents Aged 12 Through... - August 30th, 2022
- Genetics in fiction - Wikipedia - August 14th, 2022
- Weeds superpower could help feed the planet - Freethink - August 14th, 2022
- POSEIDA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - Marketscreener.com - August 14th, 2022
- Novartis Confirms Deaths of Two Patients Treated with Gene Therapy Zolgensma - Genetic Engineering & Biotechnology News - August 14th, 2022
- LETTER TO THE EDITOR: Lessons from 1984 | Letters To Editor | carolinacoastonline.com - Carolinacoastonline - August 14th, 2022
- How Arkeon Biotechnologies is turning CO2 into food: 'Excuse my language, but this is next-level cool' - FoodNavigator.com - August 14th, 2022
- Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks - PR Newswire - August 14th, 2022
- THE SAD STORY OF THE REJECTION OF SCIENCE - Sp Supplements - DAWN.COM - DAWN.com - August 14th, 2022
- Global Genome Editing Technologies market is projected to grow at a CAGR of 15.96% by 2032: Visiongain Reports Ltd - Yahoo Finance - August 5th, 2022
- I Got Critiqued by YouTuber Gutsick Gibbon - Discovery Institute - August 5th, 2022
- CRISPR Technology in the Agricultural Industry: Patent and Regulatory Updates - JD Supra - August 5th, 2022